Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Background: The aims of this study were to explore the relationship between early reduction in psychotic symptoms and the ultimate response in patients with schizophrenia treated by atypical antipsychotics, and to determine the best time to switch or maitain the regimen. PI also explore the possible predictors for the clinical response.

Methods: One hundred eleven inpatients with acutely exacerbated schizophrenia were randomized to give optimal therapy of olanzapine, risperidone, and paliperidone in one-week run-in period and 12 weeks' intervention. All participants were assessed using Positive and Negative Syndrome Scale (PANSS). Early Response, defined as reduction of 25% in PANSS score, was examined at weeks 1, 2, 3, 4 and 8, and these ratings were used to predict ultimate response (25% PANSS reduction) at week 12. PI hypothesized that early treatment response at Week 1 or 2 could predict Week 12's treatment outcome.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Calo Psychiatric Center
• Treatments: Antipsychotic Agents; Olanzapine; Paliperidone Palmitate; Risperidone

Criteria

Inclusion Criteria:

• (1) age 18 to 65 years,

• (2) no major systemic illnesses based on physical examinations and laboratory test results,

• (3) baseline PANSS total score≧60

Exclusion Criteria:

• (1) participants not taking any antipsychotics in the previous one month,

• (2) participants were pregnant and lactating women,

• (3) history of clozapine treatment in the previous 3 months,

• (4) patients receiving long-acting antipsychotic injections in the preceding 6 months of enrollment